Shang Fangjian, Li Zihao, Feng Ji, Wang Qi, An Mengyang, Zhao Zengren, Liu Bo
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Front Bioeng Biotechnol. 2025 Aug 13;13:1593368. doi: 10.3389/fbioe.2025.1593368. eCollection 2025.
Gynecomastia, characterized by benign proliferation of male breast glandular tissue, is a prevalent condition with complex etiologies. However, the absence of effective models has hindered mechanistic investigations and therapeutic development.
In this study, we established and characterized organoids derived from the breast tissues of six male gynecomastia patients, including physiological, idiopathic, and hormone-related subtypes. Organoid fidelity was evaluated using hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), immunofluorescence (IF), and quantitative PCR (qPCR), targeting a panel of lineage-specific and proliferative markers.
The organoids recapitulated key histological and molecular features of their corresponding source tissues, including epithelial architecture and expression of CK14, CK18, Ki67, and ERα. Marker expression was generally consistent between organoids and tissues at both the protein and transcriptional levels. Notably, ERα protein levels were reduced in organoids, while ESR1 mRNA expression remained stable, suggesting post-transcriptional regulation related to culture conditions.
Our study presents a practical and reproducible protocol for generating gynecomastia-derived organoids and highlights their utility as a disease-relevant platform for future research in male breast pathology and hormone-related mechanisms.
男性乳房肥大症以男性乳腺腺组织的良性增生为特征,是一种病因复杂的常见病症。然而,缺乏有效的模型阻碍了机制研究和治疗方法的开发。
在本研究中,我们建立并鉴定了源自六名男性乳房肥大症患者乳腺组织的类器官,包括生理性、特发性和激素相关亚型。使用苏木精和伊红(H&E)染色、免疫组织化学(IHC)、免疫荧光(IF)和定量聚合酶链反应(qPCR),针对一组谱系特异性和增殖标志物评估类器官的保真度。
类器官重现了其相应来源组织的关键组织学和分子特征,包括上皮结构以及细胞角蛋白14(CK14)、细胞角蛋白18(CK18)、Ki67和雌激素受体α(ERα)的表达。在蛋白质和转录水平上,类器官和组织之间的标志物表达总体一致。值得注意的是,类器官中ERα蛋白水平降低,而雌激素受体1(ESR1)mRNA表达保持稳定,表明与培养条件相关的转录后调控。
我们的研究提出了一种实用且可重复的方案来生成源自男性乳房肥大症的类器官,并强调了它们作为男性乳腺病理学和激素相关机制未来研究的疾病相关平台的效用。